Market Overview:
Preclinical imaging has assumed a significant role in
the drug development and discovery process, which is a key factor driving the
market growth. Being a non-invasive technique, preclinical imaging has garnered
many accolades from the healthcare industry. They offer various advantages over
other imaging techniques. Preclinical imaging is relatively faster, accurate,
and can be applied to
lengthy and repetitive procedures. As per the analysis
of MRFR, the Preclinical
Imaging Market is anticipated to expand at a CAGR of 6.3% over the forecast period of 2018-2023. The preclinical imaging
market was valued at USD 2.01 Bn in 2017.
Preclinical imaging is relatively faster, accurate, and
can be applied to lengthy and repetitive procedures. Preclinical imaging has found
application across various healthcare fields such as neurology, cardiology,
cancer research, cardiac imaging, functional and anatomical neuroimaging, and
others. Technological advancements in the field of preclinical imaging which
provide enhanced diagnosis of various disease conditions and aid research on
complex experiments are likely to favor the growth of the market. Other factors
which have promoted the growth of the preclinical imaging is surging awareness
regarding the ill-effects aligned with radiation-based imaging.
Competitive
Landscape:
Bruker
Corporation (US), Aspect Imaging (Israel), Fujifilm Holdings Corporation
(Japan), MR Solutions (UK), LI-COR, Inc. (US), Miltenyi Biotec GmbH (Germany),
PerkinElmer (US), Milabs B.V. (The Netherlands), Trifoil Imaging (US), and
Mediso Ltd. (Hungary)
Segmentation:
·
The preclinical imaging market has been
segmented based on modality and reagent.
·
By modality, the preclinical imaging market
has been segmented into optical imaging system, micro-CT, nuclear imaging
system, micro-MRI, micro-ultrasound, photoacoustic imaging system, and magnetic
particle imaging systems.
·
By reagent, the preclinical imaging market
has been segmented preclinical nuclear imaging reagents, preclinical optical
imaging reagents, preclinical MRI contrast agents, preclinical ultrasound
contrast agents, and preclinical CT contrast agents. The preclinical optical
imaging reagents segment has been further segmented into bioluminescent imaging
reagents and fluorescent imaging reagents.
·
The preclinical nuclear imaging reagents
segment has been further segmented into preclinical PET tracers and Preclinical
Spect Probes.
Regional
Analysis:
Region-wise, the preclinical imaging market has been segmented
into the Americas, the Middle East & Africa (MEA), Europe, and Asia Pacific
(APAC).
The global preclinical imaging market is dominated by
North America on account of the presence of a robust healthcare infrastructure,
technological advancements in the field of molecular imaging, and the presence
of various market leaders in the region. Heightened demand for non-invasive
small-animal imaging technique combined with increasing funding by the government
to support preclinical imaging-based research are also promoting the growth of
the market.
Europe is a major R&D hub with massive support from
the governments in the form of R&D funds. Moreover, intensifying efforts by
the governments to provide improved diagnostic services in the region is likely
to spur the demand for preclinical imaging.
The APAC preclinical imaging market is anticipated to
observe the fastest growth rate over the forecast period. Improving economic
conditions and efforts to modernize the healthcare sector is speeding up the growth
of the preclinical imaging market. The presence of a massive patient pool
suffering from various chronic diseases is also boosting the demand for preclinical
imaging.
The MEA preclinical imaging market is presumed to
exhibit the least growth rate over the forecast period. The growth of the
market is majorly cornered towards the Middle East, where countries such as
UAE, Kuwait, and Saudi Arabia are investing heavily on the upgradation of the
healthcare sector.
.
No comments:
Post a Comment